Tanya Laidlaw, MD
Rheumatology · Boston, MANPI 1386690949
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $194,030 of the $243,661 with a category attached, or 79.6%. 14 manufacturers reported payments, led by Sanofi at 56.6% of the total. Reporting peaked in 2019 at $82,668 and has fallen 61.3% since, to $32,000 in 2025. Among rheumatology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 134 payments — averaging $1818.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$138K
- Regeneron Healthcare Solutions, Inc.$23K
- Astrazeneca UK Limited$13K
- GSK$13K
- AstraZeneca$12K
- Astrazeneca AB$11K
- plus $33K from 8 others
Across 855 payments — averaging $1784.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$614K
- GSK$404K
- Sanofi$398K
- Takeda Pharmaceuticals U.S.A., Inc.$52K
- Roche Products Limited$32K
- Sanofi US Services Inc.$14K
- plus $12K from 3 others
What the payments were for
- Consulting fees$194,03080%
- Speaking & faculty fees$8,0043%
- Travel & lodging$39,28616%
- Food & beverage$2,1511%
- Education$1890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 57 | $137,955 |
| Regeneron Healthcare Solutions, Inc. | 15 | $23,199 |
| Astrazeneca UK Limited | 4 | $13,176 |
| GSK | 14 | $12,998 |
| AstraZeneca | 16 | $12,428 |
| Astrazeneca AB | 5 | $11,131 |
| Regeneron | 4 | $8,290 |
| Eli Lilly | 6 | $7,200 |
| Sanofi-aventis U.S. LLC | 3 | $5,504 |
| Sanofi US Services Inc. | 2 | $4,893 |
| Optinose US, Inc. | 5 | $4,372 |
| Vertex | 1 | $1,590 |
| Amgen | 1 | $859 |
| Genentech USA, Inc. | 1 | $66 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$243,661 in reported general payments places this provider in the 95th percentile of 265 rheumatology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 25 | $92,512 |
| TezspireTezepelumab-Ekko | 12 | $55,688 |
| Zileuton ErZileuton | 25 | $44,342 |
| Dupixent SyringeDupilumab | 11 | $44,194 |
| Wixela InhubFluticasone Propion/Salmeterol | 25 | $4,821 |
| Montelukast Sodium | 12 | $116 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire | $12,428 | $55,68812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 265 rheumatology providers in Massachusetts.
Other rheumatology in Boston
- Marilyn PikeBoston$1.4M
- John StoneBoston$926K
- Lee SimonBoston$600K
- Jeffrey SparksBoston$299K
- Tuhina NeogiBoston$242K
- Michael WeinblattBoston$228K
- Michael BrennerBoston$115K
- Zachary WallaceBoston$106K
- Flavia CastelinoBoston$96K
- Joerg ErmannBoston$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.